NAMCP’s Spring Managed Care Forum
HepQuant’s Paige Nardi (VP, Market Access, Billing & Reimbursement) and Kerry Whitaker (Senior Medical Science Liaison) will be attending NAMCP’s Spring Managed Care Forum on April 24–25 at Rosen Creek, Orlando, FL. Stop by Booth 216 to meet with them!
EASL Congress 2025
HepQuant’s own Dr. Gregory T. Everson, CEO will present two posters at EASL Congress 2025 in Amsterdam, the Netherlands May 7 – 10. Top Poster #507 “Quantifying liver function by cholate clearance in extracorporeal circuits with a genetically modified porcine liver and brain-dead human decedent” and poster #355 “The HepQuant…
DDW 2025
Dr. Gregory T. Everson, CEO and founder of HepQuant, will discuss “Simultaneous Quantification of Native Human Liver and Porcine Liver Function in an Extracorporeal Circuit Using IV 13C-Cholate.” at the upcoming DDW 2025 Late-Breaking Plenary session on May 3, 2025. Please join him in Room 25 from 2:00 to 3:00 pm…
Global Hepatitis Summit 2025
HepQuant’s Dr. Joanne Imperial, Chief Medical Officer, will be attending the Global Hepatitis Summit 2025 in Los Angeles and presenting a poster titled HepQuant DuO™ for Quantifying Liver Function and Physiology in the Clinic: Diagnostic Performance for Esophageal Varices in Patients with Treated and Active Chronic Hepatitis C, poster P-187.
5th Annual Liver Connect Conference
HepQuant will participate in the 5th Annual Liver Connect Conference in San Antonio, TX. A silver sponsor of the event, the HepQuant team may be found at booth 17 in the exhibit hall. Three posters submitted by HepQuant will be featured during the conference. Poster 47: Initial Clinical Experience with…
AASLD, The Liver Meeting
HepQuant is excited that six abstracts, will be presented, three of which were deemed a Poster of Distinction, at The Liver Meeting 2024 on 11/16/24 and 11/17/24 linked below. Poster of Distinction: The Oral Cholate Challenge Test Defines Likelihood of Large Esophageal Varices in an Overweight and Obese US Population …
